Jon Congleton - 29 Apr 2026 Form 4 Insider Report for Avalyn Pharma Inc. (AVLN)

Role: Director
Signature: /s/ Douglas Carlson
Issuer symbol: AVLN
Transactions as of: 29 Apr 2026
Net transactions value: $0
Form type: 4
Filing time: 01 May 2026, 18:32:47 UTC
Previous filing: 15 Apr 2026
SEC: View on sec.gov

Quoteable Key Fact

"Jon Congleton filed Form 4 for Avalyn Pharma Inc. (AVLN) on 01 May 2026."

Quick Takeaways

This page summarizes Jon Congleton's Form 4 filing for Avalyn Pharma Inc. (AVLN).
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 01 May 2026, 18:32.

What Changed

Previous filing in this sequence was filed on 15 Apr 2026.
Current net transaction value: $0.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Director
Address: C/O AVALYN PHARMA INC., 105 W FIRST STREET, BOSTON
Signature: /s/ Douglas Carlson
Signature date: 01 May 2026

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

AVLN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +26,978
Change %
Price: $0.000000^*
Shares after: 26,978
Date: 29 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,978
Exercise price: $18.00
Footnotes: F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .